FEB 24, 2016 7:00 AM PST

Precision Medicine Approaches and the Future of Drug Development in Oncology

Speaker
  • Strategic Innovation Leader, Pharma Development, Roche Diagnostics
    Biography
      Tom Metcalfe joined Pharma Development (PD) Strategic Innovation as a Strategic Innovation Leader in March 2015. The Strategic Innovation group has the task of enabling PD to meet the challenges of 2020 and beyond by building innovative new skills, capabilities, processes and organizations. Tom's particular focus is on Precision Medicine. Prior to this appointment Tom worked for a year leading part of Project TRINiTY, a project within the Roche Pharma Regulatory Community in Europe. He rejoined Roche from Oncotest GmbH where he was Managing Director and co-CEO. Oncotest is a preclinical CRO which assesses the preclinical efficacy of oncology molecules using well characterized Patient Derived Tumorgrafts.

      Before this Tom spent 18 years working for Roche in a variety of functions. He joined Roche's Diagnostics business in 1993. In 1998 he was appointed Global Head of Strategic Marketing of Roche Applied Sciences. In 2001 he moved to Roche Molecular Diagnostics as Head of BD and the Clinical Genomics business. In 2004 Tom joined Roche Pharma as Global Head of the Roche Biomarker Program and from 2007 onwards became Head of Roche's Personalised Healthcare Portfolio. In 2010 Tom joined the Translational Research Sciences group of Roche's Pharma Research and Exploratory Development organization, where he was responsible for external collaborations.

      Tom studied Biochemistry at King's College, London University in 1982 and gained an MBA from the Open University, UK in 1996.

      Tom also spent 18 months between 2009 and 2011 as chair of the European Biopharmaceutical Enterprises' Task Force on Personalised Medicines.

    Abstract

    A number of recently publications have heralded the advent of Precision Medicine in Oncology, where next generation sequencing technology, other ’omics technologies, serial biopsies, sophisticated treatment algorithms and access to databases detailing response to therapy by molecular subtype can be applied to an individual cancer patient’s genomic profile to generate a specific “matching” cancer treatment. This matching treatment can subsequently be modified, with the help of additional biopsies and further analysis, to continue to match the cancer’s specific genomic characteristics upon disease progression.
     
    Many cancers with poor prognoses are characterized by high genomic heterogeneity and rapid escape from therapy. Outcomes improvements in patients suffering from these and other similar cancers will likely continue to be very difficult to achieve unless Precision Medicine approaches are applied. However, in order for the practice of Precision Medicine in Oncology to advance several major challenges must be overcome:

    1. Development of detailed standards for the identification and reporting of actionable somatic genomic variants in cancer patient samples
    2. Establishment of data repositories, adhering to actionable somatic genomic variant calling standards, for recording cancer patient responses to therapy and matching the responses to their genomic profiles
    3. Clinical validation of the algorithm generation approach
    4. Development of frameworks to allow companies to collaborate and to give treating oncologists access to a broad range of experimental medicines, allowing them to treat patients with optimal combinations
    5. Clinical programs and regulatory frameworks supporting these approaches, allowing successful approaches to be commercialized 

    Many of these challenges require broad collaborations across company and specialization boundaries to involve academics, treating clinicians, pathologists, regulators and diagnostic, pharma and IT companies. My presentation will focus on the drug development challenges which will likely follow the application of precision medicine approaches in the field of oncology.

    Learning Objectives:
    1. Understanding the impact that Next Gen. Sequencing will have on Oncology Drug Development
    2. Understanding the opportunities and challenges which are likely to arise as  consequence of the implementation of Precision Medicine approaches in Oncology.
     


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    Loading Comments...
    Show Resources
    Attendees
    • See more